Daunorubicin has been used in the treatment of six cases of acute lymphoblastic and thirteen cases of acute myeloblastic and mono-myeloblastic leukaemia.
Complete remissions were obtained in eight patients, three with acute lymphoblastic leukaemia and five with acute myeloblastic leukaemia.
Marrow aplasia makes the drug difficult to administer, but no patients died from this cause, in this series.
In some patients good remissions were obtained with relatively low doses of daunorubicin after preliminary treatment with 6-mercaptopurine.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.